Business Context and Reporting Period
This Form 8-K Current Report was filed by P3 Health Partners Inc. on August 29, 2024. The filing addresses Item 5.02 regarding the departure of a certain officer and the appointment of a new Chief Financial Officer (CFO).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Transition: Atul Kavthekar resigned as Chief Financial Officer effective October 1, 2024. His resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- New Appointment: Leif Pedersen was appointed as Chief Financial Officer, effective October 1, 2024. He will also serve as the principal financial officer and principal accounting officer.
- Advisory Role: Mr. Kavthekar is expected to serve as an advisor to the Company following his departure.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for the new CFO, Leif Pedersen, effective September 3, 2024:
- Base Salary: $440,000 annually.
- Target Bonus: Eligible for a target annual bonus equal to 50% of the base salary.
- Equity Awards: A total of 1,500,000 shares of Class A common stock were granted under the 2021 Incentive Award Plan:
- Stock Options: 750,000 shares subject to time-based vesting (25% on the first anniversary, remaining 75% quarterly over three years).
- Restricted Stock Units (RSUs): 750,000 shares subject to both service-vesting (matching the option schedule) and performance-vesting conditions. The performance condition is tied to the closing of the first underwritten offering and sale of Class A Common Stock following the grant date.
- Severance: If terminated without cause after six months of employment, Mr. Pedersen is entitled to cash severance equal to six months of his annual base salary, subject to mitigation.
- Change in Control: Accelerated vesting provisions apply in the event of a Qualifying Change in Control or a CPF Transaction.
Investor Verification Checklist
- Verify the effective date of the CFO transition (October 1, 2024) and the interim financial reporting responsibilities.
- Confirm the status of the "first underwritten offering" required for the performance vesting of Mr. Pedersen's RSUs.
- Review the Company's 2021 Incentive Award Plan to understand the full terms of the equity grants.
- Monitor future filings for any financial updates or strategic shifts resulting from the new CFO's appointment.